AC Immune SA (ACIU – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a $16.00 price target.
Andrew Fein has given his Buy rating due to a combination of factors involving AC Immune SA’s recent developments and its strategic partnership with Takeda. The collaboration with Takeda lends credence to AC Immune’s methodology for treating Alzheimer’s disease (AD), particularly with their active immunotherapy vaccine, ACI-24.060. This partnership came at a pivotal moment, coinciding with positive preliminary data and the advent of the ABATE study’s initial outcomes. Fein views the Takeda deal as a significant de-risking milestone that financially supports the vaccine’s development pathway and underscores the pharmaceutical industry’s growing interest in diverse approaches to AD treatment.
Furthermore, Andrew Fein’s optimism is bolstered by the ABATE study’s design and early encouraging signs of plaque reduction in AD patients. The study’s adaptive nature, which includes multiple interim analyses based on biomarkers, provides a robust framework for evaluating the vaccine’s efficacy and safety. Importantly, the study targets prodromal AD patients, which may lead to more favorable cognitive and clinical outcomes. Fein anticipates that forthcoming interim data could help AC Immune refine the vaccine dosing to achieve amyloid plaque reduction, a significant indicator of potential clinical benefits. All these elements contribute to Fein’s positive outlook and Buy rating for AC Immune SA.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
AC Immune SA (ACIU) Company Description:
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Read More on ACIU:
